Jusvinza e interleucina-17, amplificador silencioso de la COVID-19

RAFAEL MIRANDA PEDROSO

Jusvinza e interleucina-17, amplificador silencioso de la COVID-19

RAFAEL MIRANDA PEDROSO

Texto completo:

PDF

Resumen

Jusvinza o CIGB 258 es un nuevo fármaco creado inicialmente para el tratamiento de la artritis reumatoide; pero por su mecanismo de acción, ha demostrado ser beneficioso en el tratamiento de la neumonía grave en el curso de la infección por SARS-CoV-2.

Palabras clave

Jusvinza; CIGB 258; COVID-19

Referencias

Referencias bibliográficas

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary vascular endothelialitis, thrombosis and angiogenesis in Covid-19. The New England Journal of Medicine [Internet]. 2020 [cited 2022 Oct 14]; 383 (2). 120–128. Available in: https://doi.org/10.1056/NEJMoa2015432

Shibabaw Inflammatory Cytokine: IL-17A Signaling Pathway in Patients Present with COVID-19 and Current Treatment Strategy. Journal of inflammation research, [Internet]. 2020 [cited 2022 Oct 14]; 13:673–680. Available in:

https://doi.org/10.2147/JIR.S278335

Wu D, Yang, XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. Journal of microbiology, immunology, and infection, [Internet]. 2020 [cited 2022 Oct 14]; 53(3): 368–370. Available in:

https://doi.org/10.1016/j.jmii.2020.03.005

Leija Martínez JJ, Huang F, Del Río Navarro BE, Sanchéz Muñoz F, Muñoz Hernández O, Giacoman Martínez A. IL-17A and TNF-α as possible biomarkers of acute respiratory distress syndrome and mortality in patients with obesity and COVID -19 Medicine. Hypothesis [Internet]. 2020 [cited 2022 Oct 14]; 144, Article 109935. Available in: https://doi.org/10.1016/j.mehy.2020.109935

Maione F, Casillo GM, Raucci F, Salvatore C, Ambrosini G, Costa L, et al. Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomedicine & pharmacotherapy, [Internet]. 2021 [cited 2022 Oct 14]; 142, 111980. Available in: https://doi.org/10.1016/j.biopha.2021.111980

Ly K, Smith MP, Thibodeaux Q, Reddy V, Liao W, Bhutani T. Anti IL-17 in psoriasis. Expert Rev Clin Immunol, [Internet]. 2019 [cited 2022 Oct 14]; 15(11):1185-94. Available in: https://doi.org/10.1080/1744666X.2020.1679625.

O'Rielly DD, Rahman P. A review of ixekizumab in the treatment of psoriatic arthritis. Expert Rev Clin Immunol, [Internet]. 2018 [cited 2022 Oct 14]; 14(12):993-1002. Available in: https://doi.org/10.1080/1744666X.2018.1540931.

Frieder J, Kivelevitch D, Haugh I, Watson I, Menter A. Anti-IL-23 and anti-IL-17 biological agents for the treatment of immune-mediated inflammatory conditions. Clin Pharmacol Ther, [Internet]. 2018 [cited 2022 Oct 14]; 103(1):88-101. Available in: https://doi.org/10.1002/cpt.893.

Venegas Rodríguez R, Peña Ruiz R, Santana R, Bequet Romero M, Hernández Cedeño M, Santiesteban-Licea B, et al. CIGB-258 immunomodulatory peptide for the treatment of severe and critical patients with COVID-19. Cuban Journal of Military Medicine [Internet]. 2020 [cited 2022 Oct 15]; 49 (4) Available in: http://www.revmedmilitar.sld.cu/index.php/mil/article/view/926

Barberá A, Lorenzo N, van Kooten P, van Roon J, de Jager W, Prada D, et al. APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patients. Cell stress & chaperones, [Internet]. 2016 [cited 2022 Oct 15]; 21(4), 735–744.Available in: https://doi.org/10.1007/s12192-016-0698-0

Dominguez Horta MC, Venegas Rodríguez R, Guillén Nieto G, Martínez Donato G, Hernández Cedeño M, Bequet Romero M, Peña Ruiz R, Santana Sánchez R, González L, Cabrales A, Padrón G, Cruz L, Esquivel-Moynelo I CIGB-258, peptide inhibitor of hyperinflammation in patients with COVID-19. Annals of the Cuban Academy of Sciences [Internet]. 2022 [cited 2022 Oct 15]; 12 (1) Available in: http://revistaccuba.sld.cu/index.php/revacc/article/view/1072

Hernández Cedeño M, Venegas Rodriguez R, Peña Ruiz R, Bequet Romero M, Santana Sanchéz R, Penton Arias E, Martinez Donato G, Guillén-Nieto G, Dominguez Horta, M. (2021). CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients. Cell stress & chaperones, [Internet]. 2021 [cited 2022 Oct 15] 26(3), 515–525. Available in: https://doi.org/10.1007/s12192-021-01197-2

Sánchez Pérez D, Fernández Álvarez L, Cruz Fernández E. Treatment with anti-inflammatories in high-risk Covid 19 patients, evolution of the disease, presentation of a clinical case. SA [Internet]. 2022 May 1 [cited 2022 Oct 15]; 5(2):60-72. Available in: http://www.sinergiaacademica.com/index.php/sa/article/view/83

Enlaces refback

No hay ningún enlace refback.